Technical Analysis for AERI - Aerie Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 21.96 -2.01% -0.45
AERI closed down 2.01 percent on Tuesday, July 23, 2019, on 1.4 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Down Down
See historical AERI trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -2.01%
New 52 Week Low Weakness -2.01%
Wide Bands Range Expansion -2.01%

Older signals for AERI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:
Profile
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its product candidates include dual-action AR-13324, a once-daily eye drop to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension, which has completed a Phase IIb clinical trials; triple-action PG324, a single drop fixed-dose combination of AR-13324 and latanoprost for the treatment of patients with glaucoma; and AR-13533, a dual-action ROCK/NET inhibitor that is in preclinical development stage. The company was founded in 2005 and is headquartered in Bedminster, New Jersey.
Chemistry Pharmaceutical Diseases Chemical Compounds Organic Compounds Glaucoma Alcohols Cyclopropanes Aerie Pharmaceuticals Intraocular Pressure Ocular Hypertension Prostaglandins
Is AERI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jul 18 Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
Jul 18 Hatteras Ventures-backed firm adds fresh round of capital
Jul 15 Aerie Pharmaceuticals: Guidance Is Unachievable After Failed Drug Launches; 70%+ Downside
Jul 11 How a Durham firm stands to benefit from an unexpected break in a Japanese trial
Jul 9 Aerie Completes Enrollment Under Rhopressa Study in Japan
Jul 9 The Daily Biotech Pulse: Roche Presents Positive Hemlibra Data, Amgen's Tender Offer For Nuevolution Complete, Genmab Offering
Jul 9 Aerie Pharma completes enrollment in mid-stage netarsudil study in Japan
Jul 9 Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule
Jul 3 The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief
Jul 2 The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug
See more AERI news...
Indicators
Indicator Value
52 Week High 72.1
52 Week Low 21.78
Average Volume 673,335
200-Day Moving Average 41.4595
50-Day Moving Average 32.1656
20-Day Moving Average 25.889
10-Day Moving Average 24.184
Average True Range 1.3089
ADX 55.94
+DI 6.3706
-DI 36.1029
Chandelier Exit (Long, 3 ATRs ) 28.0633
Chandelier Exit (Short, 3 ATRs ) 25.7067
Upper Bollinger Band 30.3456
Lower Bollinger Band 21.4324
Percent B (%b) 0.06
BandWidth 34.428522
MACD Line -2.7175
MACD Signal Line -2.6678
MACD Histogram -0.0497
Fundamentals Value
Market Cap 797.91 Million
Num Shares 36.3 Million
EPS -3.26
Price-to-Earnings (P/E) Ratio -6.74
Price-to-Sales 0.00
Price-to-Book 12.18
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.31
Resistance 3 (R3) 23.40 23.04 23.09
Resistance 2 (R2) 23.04 22.70 23.00 23.01
Resistance 1 (R1) 22.50 22.48 22.32 22.41 22.93
Pivot Point 22.14 22.14 22.05 22.10 22.14
Support 1 (S1) 21.60 21.80 21.42 21.51 20.99
Support 2 (S2) 21.24 21.58 21.20 20.91
Support 3 (S3) 20.70 21.24 20.84
Support 4 (S4) 20.61